Molteni Farmaceutici Polska was the first to introduce ropivacaine to the Polish market. The available concentrations of the drug are: 2 mg/ml, 5 mg/ml, 7.5 mg/ml, and 10 mg/ml. Depending on the concentration, the indications for use include: postoperative analgesia, spinal anesthesia, epidural anesthesia, sacral anesthesia in children, local blocks, and peripheral nerve blocks. Particular attention should be given to the possibility of using ropivacaine in epidural anesthesia for physiological childbirth. Ropivacaine, classified by the FDA for pregnancy as Category B, currently represents the safest option for both mother and child. The “walking anesthesia” technique allows for faster mobilization of the patient after childbirth.
